Abstract:Lung cancer is the commonest cancer killer worldwide. Tyrosine-kinase inhibitors (TKI) are novel agents in the treatment of this cancer. However, their efficacy is impaired by the rapid development of drug-resistance through a variety of mechanisms. Here, we will discuss resistance to the first-generation EGFR inhibitors (e.g. Erlotinib) and SRC inhibitors (e.g. Dasatinib). The principal mechanism of resistance to first-generation EGFR inhibitors is the appearance of the T790M receptor mutation. While the reason for resistance was proposed to be changes in affinity of the receptor for ATP, our metabolomics analysis additionally revealed that resistance is associated with decreased cellular levels of glutathione (GSH), a direct consequence of the T790M mutation. This occurred because of decreased SQSTM1/NRF2-mediated transcription of GSH synthesising enzymes in cell lines and clinical samples with T790M-EGFR. We demonstrate that increasing GSH levels in resistant cells re-sensitises these to first-generation EGFR inhibitors in vitro and in vivo. As compounds exist in the clinic to achieve this, our finding may have profound therapeutic and economic consequences. Src family kinases (SFK) are commonly overexpressed or hyperactivated in lung cancer cell lines and clinical samples. However, despite their on-target efficacy, SRC inhibitors have failed to prevent tumour growth and improve patients' survival in multiple clinical trial. Here we show that this failure is associated with the induction of autophagy in treated cells that prevents these compounds from triggering apoptosis cell death. Targeting autophagy, either genetically or using our novel small-molecule inhibitor, C1A, sensitises lung cancer cell lines to Dasatinib both in vitro and in vivo by unlocking the apoptotic response. These findings propose new combinational therapeutic strategies that could resurrect the use of SRC inhibitors in the treatment of lung cancer.

Advances of Autophagy and EGFR-TKI Drug Resistance in the Treatment of Non-Small Cell Lung Cancer

EGFR-TKI Resistance in NSCLC Patients: Mechanisms and Strategies.

Cotargeting EGFR and autophagy signaling: A novel therapeutic strategy for non-small-cell lung cancer.

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature

[Research Progress of the Role of EMT in EGFR-TKIs Resistance of Non-small Cell Lung Cancer].

Updates on Resistance Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-cell Lung Cancer

Targeted Therapy for Non-Small-cell Lung Cancer Using EGFR-TKIs

The Treatment of EGFR-TKI Resistance in Non-small Cell Lung Cancer

Advances in research on EGFR-TKI resistance mechanism and therapeutic strategies in non-small cell lung cancer

Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy

Research progress of immunotherapy in epidermal growth factor receptor mutant advanced non-small cell lung cancer

Mechanism and Treatment Associated with Resistance to EGFR-TKI

Advances in mechanism of drug resistance to EGFR-TKIs for non-small cell lung cancer and possible solutions

Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma

[Research Progress on Resistance Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer].

Novel considerations on EGFR-based therapy as a contributor to cancer cell death in NSCLC

EGFR Tyrosine Kinase Inhibitors Activate Autophagy As a Cytoprotective Response in Human Lung Cancer Cells

Progress of EGFR-targeted Therapy for NSCLC

Resistance to Tyrosine Kinase-Targeted Therapy in Lung Cancer: Autophagy and Metabolic Changes

Nanomodified strategies to overcome EGFR-tyrosine kinase inhibitors resistance in non-small cell lung cancer

Immunotherapy-based Combination Strategies for Treatment of EGFR-TKI-resistant Non-Small-cell Lung Cancer